Why Patients Switch Between Mounjaro and Wegovy Treatments
Understanding Mounjaro v Wegovy Doses When Making the Switch
When comparing Mounjaro v Wegovy doses, the key difference lies in their mechanisms and dosing schedules. Wegovy (semaglutide) follows a structured escalation: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, and 2.4mg for maintenance from week 17. Mounjaro (tirzepatide) uses a different scale entirely, starting at 2.5mg and escalating to 5mg, 7.5mg, 10mg, and maximum 15mg doses. This fundamental difference means direct dose conversions aren't straightforward—your prescriber will determine the appropriate Wegovy starting dose based on your current Mounjaro response and tolerability.
The Switch & Save approach becomes particularly valuable when transitioning between these medications, as many patients find Wegovy's GLP-1-only mechanism suits them better than Mounjaro's dual GIP/GLP-1 action. Some experience fewer gastrointestinal side effects with semaglutide, while others prefer the storage advantages—Wegovy remains stable at room temperature for 6 weeks compared to Mounjaro's 21-day limit. At EverydayMeds, we've designed our pricing structure to make switching between Mounjaro v Wegovy doses financially accessible, recognising that finding your optimal treatment may require trying both options.
Wegovy Pricing Structure: Switch & Save Opportunities
Our Switch & Save pricing makes transitioning between Mounjaro v Wegovy doses more affordable than ever. Single Wegovy pens start at £79.99 for the 0.25mg starter dose, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. New customers benefit from discount code FIRST40, while returning customers use DOSE25—both codes are applied at checkout to reach these final prices. Many patients switching from Mounjaro find significant monthly savings, particularly when reaching Wegovy's maintenance phase.
Our bundle options provide additional convenience for those committed to the switching process. The Intro Duo (0.25mg & 0.5mg) costs £169.99, perfect for patients beginning their Wegovy transition, while the Progress Duo (0.5mg & 1mg) at £189.99 supports continued dose escalation. For patients confident in their switch, our Intro Trio (0.25mg, 0.5mg & 1mg) provides three months of step-up treatment for £299.99. These bundles eliminate the need for multiple orders during your transition period, ensuring uninterrupted treatment while you adjust to your new medication regimen.
Clinical Evidence Supporting Mounjaro v Wegovy Dose Transitions
Research from the STEP trial programme, particularly findings published by Wilding et al. in NEJM 2021, demonstrates that patients taking Wegovy alongside diet and exercise experienced significant weight management benefits. The STEP 1 trial showed average weight loss of approximately 15% at 68 weeks, while STEP 2 demonstrated around 9.6% weight reduction in patients with type 2 diabetes. These outcomes support why many patients consider switching when their current treatment isn't meeting expectations.
The SELECT cardiovascular outcomes trial revealed an additional benefit—a 20% reduction in major cardiovascular events among patients taking semaglutide. This evidence becomes particularly relevant for patients comparing Mounjaro v Wegovy doses who have cardiovascular risk factors. However, individual responses vary significantly, and some patients may find better tolerability or efficacy with tirzepatide's dual-action mechanism rather than semaglutide's GLP-1-only approach.
How Wegovy's Mechanism Differs in Mounjaro v Wegovy Comparisons
Wegovy works as a GLP-1 receptor agonist, mimicking your body's natural incretin hormones that regulate blood sugar and appetite. Unlike Mounjaro's dual GIP/GLP-1 action, Wegovy focuses solely on GLP-1 pathways, which may reduce appetite more predictably and promote earlier satiety after meals. The medication acts on appetite centres in your brain, potentially reducing food cravings and making portion control more manageable. This targeted approach explains why some patients switching from Mounjaro find Wegovy's effects more pronounced on hunger and eating behaviours. The once-weekly injection schedule remains consistent between both medications, making the practical aspects of switching straightforward.
Streamlined Ordering Process for Your Mounjaro v Wegovy Switch
Making the switch between Mounjaro v Wegovy doses through EverydayMeds is designed for simplicity and safety. Begin with our 3-minute online clinical assessment, where you'll detail your current medication history, previous experiences with GLP-1 treatments, and reasons for switching. Our prescriber team, operating under GPhC registration #9012878, reviews your case within 3 working days (or 24 hours with express service), determining the most appropriate starting dose based on your Mounjaro experience. Once approved, your Wegovy pen ships via next-day delivery in temperature-controlled packaging, maintaining the cold-chain integrity essential for this prescription-only medicine. This seamless process ensures no treatment gaps during your transition period.
Storage and Practical Considerations When Switching Doses
Storage represents a key advantage when comparing Mounjaro v Wegovy doses for practical lifestyle considerations. Wegovy maintains stability for up to 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day limit—a significant benefit for frequent travellers or those with limited fridge space. The FlexTouch pen delivery system remains intuitive, with clear dose windows and simple injection mechanics. Your dose escalation schedule is non-negotiable—each dose level must be completed for the full 4-week period before progression, ensuring your body adjusts gradually to avoid gastrointestinal side effects. Store unopened pens in your refrigerator at 2-8°C, and never freeze or shake the medication.
Why Switch & Save Makes Sense for Mounjaro v Wegovy Patients
The Switch & Save approach recognises that finding optimal weight management treatment often requires trying different medications. Many patients begin with Mounjaro due to its dual-action mechanism but discover that Wegovy's GLP-1-only approach better suits their physiology and lifestyle. Cost considerations also drive switching decisions—our competitive Wegovy pricing often provides monthly savings compared to other suppliers, particularly when factoring in our discount codes.
Some patients switch due to availability issues or insurance coverage changes, while others find semaglutide causes fewer side effects than tirzepatide. The beauty of having both Mounjaro v Wegovy available from EverydayMeds means you're not tied to a single treatment pathway. Your prescriber can recommend switching strategies based on your individual response, medical history, and treatment goals, ensuring you receive the most appropriate medication for your circumstances.
Complete Your Mounjaro v Wegovy Dose Transition Today
Ready to explore switching between Mounjaro v Wegovy doses with our Switch & Save programme? Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and discuss transition options with our prescriber team. New customers should apply discount code FIRST40 at checkout, while returning customers benefit from DOSE25—both codes are built into our final pricing structure. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine, properly stored medication with full clinical support throughout your switching journey. Remember, both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which medication aligns best with your weight management goals and medical profile.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
